Trastuzumab Duocarmazine
HER2 Positive Breast Carcinoma
QuantumLeap Healthcare Collaborativeantibody_drug_conjugatePhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 65/ 100
Competitive context
175 Active assets in the HER2 Positive Breast Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB SWOG Cancer Research Network | Phase 4 | BB |
Pertuzumab SWOG Cancer Research Network | Phase 4 | BB |
Ribociclib Danish Breast Cancer Cooperative Group | Phase 3 | BB |
Docetaxel Ohio State University Comprehensive Cancer Center | Phase 3 | BB |
Capecitabine MedSIR | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Trastuzumab Duocarmazine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →